UltraAvidin™- PE

Pricing & Details

Prod No.
Add to cart
A104-0.5 mg
0.5 mg
In stock
A104-1.0 mg
1.0 mg
In stock
Host Species
Chicken Egg White
Product Concentration
1.0 mg/ml
UltraAvidin-R-phycoerythrin is supplied in 0.01M phosphate buffered saline (PBS) pH 7.4, containing 1.0% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This PE conjugate is stable when stored at 2-8°C. Do not freeze.
Isoelectric Point
pI= 6.3 +/- 0.3
Specific Activity
11-17 µg biotin bound/mg UltraAvidin™
Applications and Recommended Usage ?
(Quality Tested by Leinco)
Flow Cytometry: This antibody has been quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. Each investigator should determine their own optimal working dilution for specific applications.


UltraAvidin™ is Leinco Technologies' trademark for a uniquely modified form of avidin which is isolated from chicken egg whites. With a molecular weight of 60,000, there are four identical subunits each capable of binding one molecule of biotin. UltraAvidin from Leinco Technologies has been de-glycosylated to prevent carbohydrate moieties from adhering to lectin-like receptors on the surface of cells, thus eliminating the possibility of false positives. Unlike native avidin, UltraAvidin has a near neutral pI which prevents electrostatic interactions with negatively charged serum or membrane proteins.

Recent studies have identified a universal recognition sequence in streptavidin which is similar to that found in several adhesion receptors.4 It is a tripeptide sequence Arg-Tyr-Asp (RYD) which mimics the Arg-Gly-Asp (RGD) binding sequence of fibronectin. Strong interactions have been shown with streptavidin and cell surface molecules. This universal recognition sequence is not present in UltraAvidin. UltraAvidin may not significantly increase sensitivity in all research systems but will help assure specificity.

References & Citations

1. Frelinger, JA. et al. (2007) Blood. 109(8): 3300–3307. PubMed
2. Rénia, L. et al. (2003) Infect Immun. 71(6):3648-51. PubMed
3. Rénia, L. et al. (2002) J Immunol. 169(11):6369-75. Article Link
4. Wilchek, M. et al. (1990) Biochem Biophys Res Commun.170(3):1236-41.
5. Sullivan, W. et al. (1996) Genetics. 143(4):1629-42.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.